Could white blood cells drive skin scarring in scleroderma?
NCT ID NCT03816189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study examined whether eosinophils, a type of white blood cell, contribute to fibrosis (scarring) in systemic sclerosis, an autoimmune disease. Researchers compared blood samples from 40 patients with systemic sclerosis and 30 healthy volunteers, with optional skin biopsies. The goal was to understand how eosinophils might promote tissue damage, which could inform future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new targets for treating fibrosis in systemic sclerosis.
- What could go wrong
- This is an observational study with only 70 participants, so findings may not apply broadly or lead directly to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLERODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts